MSB themselves are guiding analysts and shareholders to expect a future adult GvHD trial as a backup to Ruxolitinib:
So they are aiming to be a third-line treatment. I’m not sure how much clearer the point can be made: Adult HR-aGvHD is still a wide open market for Cynata to target. As for off-label use, I think Pfeifer summed it up pretty clearly. If you think that clinicians are going to prioritise a therapy approved for a tiny portion of a subset of a disease, where the company who make said therapy are openly telling you it should be used as a last resort, then I have some magic beans I would like to sell you.
CYP Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
